Imfinzi and Imdelltra cut risk of dying by 58% in lung cancer of the small-cell type

In the Phase III DeLLphi-305 trial, patients given Imfinzi alongside Imdelltra as initial treatment for extensive-stage lung cancer of the small-cell type had a 58% lower risk of death.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.